These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 24556643)
21. [Establishment and characterization of dual-color fluorescence nude mouse models of glioma]. Zhang J; Lu Z; Fei X; Dai X; Wu J; Wan Y; Wang Z; Wang A; Dong J; Lan Q; Huang Q Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):97-102. PubMed ID: 24796456 [TBL] [Abstract][Full Text] [Related]
22. Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities. Groblewska M; Mroczko B Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200145 [TBL] [Abstract][Full Text] [Related]
23. Biochanin A inhibits endothelial cell functions and proangiogenic pathways: implications in glioma therapy. Jain A; Lai JC; Bhushan A Anticancer Drugs; 2015 Mar; 26(3):323-30. PubMed ID: 25501542 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879 [TBL] [Abstract][Full Text] [Related]
25. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903 [TBL] [Abstract][Full Text] [Related]
26. Angiogenesis and antiangiogenic therapy for malignant gliomas. Takano S; Kamiyama H; Tsuboi K; Matsumura A Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836 [TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Strieth S; Eichhorn ME; Sutter A; Jonczyk A; Berghaus A; Dellian M Int J Cancer; 2006 Jul; 119(2):423-31. PubMed ID: 16477628 [TBL] [Abstract][Full Text] [Related]
28. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629 [TBL] [Abstract][Full Text] [Related]
29. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. Vajkoczy P; Schilling L; Ullrich A; Schmiedek P; Menger MD J Cereb Blood Flow Metab; 1998 May; 18(5):510-20. PubMed ID: 9591843 [TBL] [Abstract][Full Text] [Related]
30. Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D ΔR2-μMRA. Lin CY; Siow TY; Lin MH; Hsu YH; Tung YY; Jang T; Recht L; Chang C Angiogenesis; 2013 Oct; 16(4):785-93. PubMed ID: 23736837 [TBL] [Abstract][Full Text] [Related]
32. How does antiangiogenic therapy affect brain tumor response to radiation? Weichselbaum RR Nat Clin Pract Oncol; 2005 May; 2(5):232-3. PubMed ID: 16264953 [No Abstract] [Full Text] [Related]
33. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143 [TBL] [Abstract][Full Text] [Related]
34. Differential expression of angiopoietin-1 and angiopoietin-2 may enhance recruitment of bone-marrow-derived endothelial precursor cells into brain tumors. Udani V; Santarelli J; Yung Y; Cheshier S; Andrews A; Kasad Z; Tse V Neurol Res; 2005 Dec; 27(8):801-6. PubMed ID: 16354539 [TBL] [Abstract][Full Text] [Related]
35. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Ho IA; Toh HC; Ng WH; Teo YL; Guo CM; Hui KM; Lam PY Stem Cells; 2013 Jan; 31(1):146-55. PubMed ID: 23034897 [TBL] [Abstract][Full Text] [Related]
36. Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. Czabanka M; Parmaksiz G; Bayerl SH; Nieminen M; Trachsel E; Menssen HD; Erber R; Neri D; Vajkoczy P Eur J Cancer; 2011 May; 47(8):1276-84. PubMed ID: 21396810 [TBL] [Abstract][Full Text] [Related]
37. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Aghi M; Cohen KS; Klein RJ; Scadden DT; Chiocca EA Cancer Res; 2006 Sep; 66(18):9054-64. PubMed ID: 16982747 [TBL] [Abstract][Full Text] [Related]
38. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623 [TBL] [Abstract][Full Text] [Related]
39. The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway. Liu D; Cao G; Cen Y; Liu T; Peng W; Sun J; Li X; Zhou H Int Immunopharmacol; 2013 Oct; 17(2):237-44. PubMed ID: 23791618 [TBL] [Abstract][Full Text] [Related]
40. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]